Suppr超能文献

阿托伐他汀对高血压患者的交感神经抑制作用。

Sympathoinhibition by atorvastatin in hypertensive patients.

机构信息

Department of Internal Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.

出版信息

Circ J. 2010 Nov;74(12):2622-6. doi: 10.1253/circj.cj-10-0427. Epub 2010 Oct 9.

Abstract

BACKGROUND

Experimental animal data suggest that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) might reduce enhanced sympathetic activity, a hallmark of hypertensive patients. This hypothesis was tested for the first time in patients with primary hypertension.

METHODS AND RESULTS

Using a prospective, randomized, placebo-controlled, double-blind, cross-over design, a proof-of-principle trial was performed in 13 patients with mild to moderate primary hypertension, who were randomly assigned to a regimen of atorvastatin (80mg/day) for 3 weeks, followed by placebo for 3 weeks or to a regimen of placebo for 3 weeks, followed by atorvastatin (80mg/day) for 3 weeks. Microneurography was used at the end of each treatment period to measure sympathetic nervous system activity (muscle sympathetic nerve activity: MSNA). Heart rate variability (HRV) and plasma norepinephrine concentrations were also measured. Additionally, effects on blood pressure (BP) and heart rate (HR) were assessed by 24-h ambulatory BP measurement. Atorvastatin reduced postganglionic MSNA (atorvastatin 35.0±2.0 vs placebo: 39.2±1.5 bursts/min, P=0.008) and heart frequency corrected MSNA (atorvastatin: 58.5±2.0 vs placebo: 64.7±3.0 bursts/100 beats, P=0.02). Atorvastatin had no significant effect on plasma norepinephrine levels, HRV, BP or HR.

CONCLUSIONS

In patients with mild to moderate hypertension, atorvastatin reduces postganglionic MSNA, which supports the hypothesis that HMG-CoA reductase plays a role in sympathetic nervous system activity.

摘要

背景

实验动物数据表明,3-羟基-3-甲基戊二酰辅酶 A(HMG-CoA)还原酶抑制剂(他汀类药物)可能降低高血压患者增强的交感神经活性,这是高血压患者的一个标志。这一假设首次在原发性高血压患者中得到了检验。

方法和结果

采用前瞻性、随机、安慰剂对照、双盲、交叉设计,对 13 例轻中度原发性高血压患者进行了一项原理验证试验,患者被随机分为阿托伐他汀(80mg/天)治疗 3 周,随后安慰剂治疗 3 周或安慰剂治疗 3 周,随后阿托伐他汀(80mg/天)治疗 3 周。在每个治疗期结束时使用微神经记录法测量交感神经系统活动(肌肉交感神经活动:MSNA)。还测量了心率变异性(HRV)和血浆去甲肾上腺素浓度。此外,通过 24 小时动态血压测量评估对血压(BP)和心率(HR)的影响。阿托伐他汀降低了节后 MSNA(阿托伐他汀 35.0±2.0 比安慰剂:39.2±1.5 次/分钟,P=0.008)和心率校正后的 MSNA(阿托伐他汀:58.5±2.0 比安慰剂:64.7±3.0 次/100 次心跳,P=0.02)。阿托伐他汀对血浆去甲肾上腺素水平、HRV、BP 或 HR 没有显著影响。

结论

在轻中度高血压患者中,阿托伐他汀降低了节后 MSNA,这支持了 HMG-CoA 还原酶在交感神经系统活性中起作用的假设。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验